Recruiting
Phase 1
Phase 2

Y90

Sponsor:

Jonsson Comprehensive Cancer Center

Code:

NCT06432036

Conditions

Stage I Renal Cell Cancer

Stage II Renal Cell Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Angiogram

Biospecimen Collection

Computed Tomography

Radioembolization

Single Photon Emission Computed Tomography

Study Details

Brief summary:

This phase I/II trial tests the safety, side effects and effectiveness of radioembolization with yttrium-90 (Y-90) in patients with early stage renal cell carcinoma. Y-90 is a radioactive chemical that is incorporated into millions of very tiny glass spheres. These spheres are injected into the artery that feeds the cancer. This process is called radioembolization. Y-90 radioembolization may be a safe and effective treatment for patients with early stage renal cell carcinoma.

Conditions

Stage I Renal Cell Cancer

Stage II Renal Cell Cancer

Study ID

NCT06432036

Start date

Dec 26, 2024

Status verified date

Feb, 2026

Completion date

Mar, 2030

Anticipated

Primary completion date

Mar 24, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participants must be aged ≥ 18 years at the time of screening
  • Written informed consent and any locally required authorization (e.g., Health Insurance Portability and accountability Act) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations
  • Life expectancy ≥ 12 months
  • RCC, diagnosed by radiographic imaging and histology
  • Clinical stage of RCC: T1 or T2a, Cancer stage (N0M0)
  • 1-2 solid (> 80% solid) target lesions
  • Patient not an ideal candidate for partial nephrectomy or thermal ablation at the time of study entry, based on the decision of the institution's multidisciplinary tumor board. Contraindications for partial nephrectomy include inability to potentially partially resect the kidney, high risk of adverse events due to medical comorbidities, or potential high risk of adverse events due to general anesthesia. Contraindications to thermal ablation include potential inability to technically place ablation probes into the tumor, central tumors which risk thermal injury to the renal collecting system
  • Patient not considered a candidate for long-term active surveillance due to oncologic risk due to tumor growth and/or tumor size
  • Patient not considered ideal candidates for radical nephrectomy due to surgical comorbidity and/or development of adverse health outcomes
  • Measurable tumor by RECIST 1.1 criteria
  • Absence of bilateral renal tumors
  • Negative serum pregnancy test in females of child-bearing potential; patients who are breast-feeding cannot participate in this trial
  • Hemoglobin ≥ 9.0 g/dL
  • Absolute neutrophil count ≥ 1.5 x 10\^9/L
  • Absolute lymphocyte count ≥ 1.0 x 10\^9/L
  • Platelet count ≥ 75 x 10\^9/L
  • Glomerular filtration rate (GFR) ≥ 45 mL/min/1.73 m\^2
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment
  • Screening mapping angiogram demonstrates successful localization of tumor(s), where catheter placement location(s) would allow Y90 to distribute in the intended treatment area, without venous shunting

Exclusion Criteria:

  • Any contraindication to angiography or selective renal artery catheterization
  • Screening angiography with cone beam CT (CBCT) shows any arterial flow to the gastrointestinal tract uncorrectable by angiographic techniques
  • Screening angiography with CBCT shows poor tumor targeting that would lead to a dose that does not meet the renal dosing criteria. This typically occurs when a feeding artery to the tumor cannot be identified
  • Screening angiography demonstrates excessive non-tumoral renal parenchyma will be in the treatment field, that the new baseline glomerular filtration rate will be < 45 mL/min/1.73 m\^2
  • Screening angiography demonstrates renal venous shunting of iodinated contrast that is immediately visible upon arterial injection
  • Extra-renal metastases, including patients with abdominal lymph nodes >1.5 cm in shorter axis, or with lung nodules (single lesion, >1 cm, or multiple smaller lesions with a total diameter >2 cm)
  • Brain metastases, leptomeningeal carcinomatosis or spinal cord compression. Patients with suspected brain metastases at screening should have an MRI (preferred) or CT each preferably with IV contrast of the brain prior to study entry
  • Evidence of any tumor invasion into the renal vein, renal artery, or renal collecting system
  • Any prior radiation therapy to the abdomen, including localized radiation therapy to the index tumor
  • Concurrent treatment for RCC or treatment in the last 6 months in another clinical study, unless it is an observational study (non-interventional) or during a non-interventional follow-up stage of an interventional study, or prior randomization to this study
  • History of active primary/acquired immunodeficiency
  • Presence of renal ureteral stent in the treatment kidney at any time
  • History of malignancy, other than RCC, within three years, with the exception of adequately treatment carcinoma in situ of the cervix, early squamous cell carcinoma or basal cell carcinoma of the skin, localized prostate cancer, ductal carcinoma in situ, or low-grade endometrial carcinoma with no myometrial invasion (negligible risk of metastases or death 5-year overall survival \[OS\] rate > 90%)
  • Major surgical procedure (as defined by the Investigator) within 28 days prior to enrollment
  • A history of severe allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically
  • Active infection
  • Female patients who are pregnant or breastfeeding or female patients of reproductive potential who are not willing to employ effective birth control from screening to 6 months after treatment
  • Unstable chronic disease or evidence of any disease or condition that would place the patient at undue risk and preclude safe use of Y90 microspheres, including but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events (AEs) or compromise the ability of the patient to give written informed consent
  • History of pulmonary insufficiency, measured by oxygen saturation of less than 90%
  • Solitary kidney
  • Patient not able to follow the study protocol requirements

Study Design

Enrollment

25 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Treatment (radioembolization, TheraSphere)

Patients undergo radioembolization with TheraSphere given intra-arterially. Patients undergo angiogram during screening, SPECT scan on study and CT scan and blood sample collection throughout the study.

Interventions

Angiogram

Undergo angiogram

Biospecimen Collection

Undergo blood sample collection

Computed Tomography

Undergo CT scan

Radioembolization

Undergo radioembolization

Single Photon Emission Computed Tomography

Undergo SPECT

Survey Administration

Ancillary study

Yttrium Y 90 Glass Microspheres

Given intra-arterially

Primary outcome measure

  • Number of treatment related adverse events [ Time Frame: Up to 2 years ]
  • Number of serious adverse events [ Time Frame: Up to 2 years ]

Central Contacts and Locations

Central contacts

Aniket U. Joglekar

310-948-8026ajoglekar@mednet.ucla.edu

Saima Chaabane

(310)794-8995schaabane@mednet.ucla.edu

Locations

UCLA / Jonsson Comprehensive Cancer Center

Recruiting

Los Angeles, California, United States, 90095

Contacts

Aniket U. Joglekar

(310) 948-8026ajoglekar@mednet.ucla.edu

Saima Chaabane

(310)794-8995schaabane@mednet.ucla.edu

Principal Investigator:

Siddharth A. Padia, MD

University of Colorado Anschutz Medical Campus

Recruiting

Aurora, Colorado, United States, 80045

Contacts

Shireen Shikak

(303) 724-5000Shireen.shikak@cuanschutz.edu

Principal Investigator:

Leigh Casadaban, MD

More Information

Sponsor

Jonsson Comprehensive Cancer Center

Last update posted

Aug 21, 2026

Last verified

Feb, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center on 2026-08-21.